KUALA LUMPUR: The long-term outlook for pharmaceutical firm Pharmaniaga Bhd
is expected to remain positive, despite weak filled-and-finished vaccine sales during the first quarter of its current financial year.
CGS-CIMB Research in a report said it projects decent earnings growth for the group in 2023 and 2024.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
